Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

Cheap OEM Software
  

Search in our Online Store
Proteins & Peptides
Filter     Order     Display # 
Date Item Title
08 Aug 2006 PAION and Lundbeck agree on conducting a second Phase III Study with Desmoteplase
04 Aug 2006 PDL BioPharma Reports Results From Phase 3 Trial of Terlipressin In Type 1 Hepatorenal Syndrome
03 Aug 2006 AEterna Zentaris Enters a License and Collaboration Agreement for Ozarelix with Nippon Kayaku for the Japanese Market
03 Aug 2006 EMEA Provides Scientific Advice On The Study Of ATryn(R) In DIC
03 Aug 2006 European Commission Approves ATryn(R)
03 Aug 2006 Biodel Inc. Raises $21 Million in Series B Financing; Top-Tier Healthcare Investors Provide Funding for Phase 3 Clinical Development of Viaject(TM) Rapid Acting Insulin for Type 1 and 2 Diabetes
02 Aug 2006 Spectrum Pharmaceuticals Announces Phase 2 Data for Ozarelix in Hormone-Dependent Prostate Cancer
02 Aug 2006 Ambrilia Announces Receipt of Milestone Payment from U.S. Licensing Partner for Late-Stage Oncology Specialty Generic, Octreotide
01 Aug 2006 NIH Researchers Find RegeneRx's Drug Candidate Regulates Key Proteins Important in Wound Repair; Research Team Offers New Insights Into TB4's Mechanism of Action
01 Aug 2006 New Data Shows Promising Antiviral Activity of AC-03 636, a Novel Drug Candidate From Alfacell Corporation
01 Aug 2006 Enzon Pharmaceuticals Announces Advancements in Its Oncology Pipeline; Oncaspar Phase I solid tumor trial begins; IND approved for rhMBL study
01 Aug 2006 Northfield Laboratories Completes Enrollment in Pivotal Phase III PolyHeme(R) Trial; Top-line Data from Study Expected in Fall
01 Aug 2006 Cleveland Biolabs Inc. (CBLI), Completes Analysis Of Data Generated In A Primate Trial Of Protectan CBLB502 Which Shows Unprecedented Increase In Survival Among Lethally Irradiated Animals
31 Jul 2006 Novo Nordisk receives approval in the EU for use of NovoRapid® in pregnancy
31 Jul 2006 Phyton Biotech Signs Development Agreement With Insmed
31 Jul 2006 Schering AG, Germany announces results of two clinical trials with sargramostim in Crohn’s disease patients
28 Jul 2006 Pharming Receives Fast Track Designation From US FDA For Recombinant Human C1 Inhibitor
28 Jul 2006 Nostrum Pharmaceuticals Obtains Worldwide Licensing Rights From IMTECH For Clinical Development Of A Novel Clot Busting Therapeutic Protein
27 Jul 2006 Co-development and Distribution Agreement on Treatment for Pancreatic Exocrine Insufficiency (SA-001) in Japan Concluded
27 Jul 2006 PLIVA and Mayne Pharma Finalise Agreement to Continue Development of G-CSF
26 Jul 2006 Boehringer Ingelheim terminates phase III study of Metalyse in out of hospital cardiac arrest
25 Jul 2006 FDA Approves Enzon's Oncaspar(R) for First-Line Use in Acute Lymphoblastic Leukemia
25 Jul 2006 Paion's Phase III Study on Target to be Fully Enrolled by Year-End
25 Jul 2006 Organon Has Started New Fertility Hormone Phase III Clinical Studies
25 Jul 2006 Shire’s ELAPRASE™ (idursulfase) Approved by the Food and Drug Administration (FDA) for Hunter Syndrome
25 Jul 2006 Debiopharm Applies for First European Marketing Authorisation for Sanvar® in France
25 Jul 2006 Acologix Announces Results of AC-100 Initial Feasibility Study for Treatment of Periodontal Disease
24 Jul 2006 Phosphagenics commences Phase I clinical trial for its transdermal insulin delivery platform TPM-02/Insulin
24 Jul 2006 Protox Acquires Phase II Cancer Program from Neurocrine and U.S. Public Health Service
21 Jul 2006 Pharming Submits Marketing Authorisation Application For Recombinant Human C1 Inhibitor In Europe
20 Jul 2006 Y's Therapeutics Clinical-Stage Compound YSPSL Granted Orphan Status in U.S. and Europe
20 Jul 2006 DNAPrint Pharmaceutical Completes Sterility Testing on Anemia Drug Cell Lines for Clinical Development
19 Jul 2006 Roche exercises its option to license Ipsen’s anti-diabetic medicine for type 2 diabetes
19 Jul 2006 Ipsen and Tercica to enter into worldwide strategic collaboration in endocrinology
19 Jul 2006 Theravance and Astellas Add Japan to Collaboration on Telavancin, Investigational Antibiotic for Serious Infections
19 Jul 2006 DNAPrint Genomics Enters Into Research Agreement With Harvard Affiliate Beth Israel Deaconess Medical Center
18 Jul 2006 Cangene's human growth hormone drug submission is accepted for review by FDA
18 Jul 2006 SemBioSys Achieves Major Insulin Milestone
18 Jul 2006 Transition Therapeutics Inc. and Novo Nordisk A/S Sign Amendment to License Agreement for Diabetes Regenerative Therapies,
17 Jul 2006 Mircera (C.E.R.A.) First Drug to Directly Convert Dialysis Patients to Once-Monthly Dosing Schedule
14 Jul 2006 Conjuchem announces clinical hold of its DAC(TM):GRF Program in HIV Lipodystrophy
13 Jul 2006 CoGenesys Receives FDA Clearance to Commence Clinical Trials of Cardeva in Patients with Chronic Heart Failure
13 Jul 2006 Nastech Pharmaceutical Company Receives FDA Communication Concerning Calcitonin-Salmon Nasal Spray
13 Jul 2006 BresaGen develops production process for G-CSF
12 Jul 2006 ZymoGenetics Begins Phase 1 Trial With IL-21 and Rituxan(R) in Patients With Non-Hodgkin's Lymphoma
12 Jul 2006 Medicis and Ipsen Decide to Focus Partnership for Reloxin Exclusively on United States, Canada and Japan
12 Jul 2006 Biopure Applies for Marketing Authorization of Hemopure(R) In the United Kingdom
12 Jul 2006 The European Medicines Agency Has Approved Kamada's Plan for a Phase 1 Clinical Trial of Alpha 1-Proteinase Inhibitor (API) Respiratory Treatment for Congenital Emphysema
11 Jul 2006 Oramed Pharmaceuticals Receives MOH and IRB Approval to Begin Phase 1 Human Trials for Oral Insulin
11 Jul 2006 Neose Provides Update on NE-180 Program
 
<< Start < Prev 21 22 23 24 25 26 27 28 29 Next > End >>
Results 1101 - 1150 of 1426

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Diabetes Drug Pipeline

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics